(44) recently reported that at least one CD4+ TCR-engineered T cell targeting one neoantigen is essential for maintenance of the efficacy of CD8+ TCR-engineered T cells together with antigen-presenting cells and cancer cells. This evidence concerns the gene CD4 and cancer.